Literature DB >> 7699543

Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease.

M A Rojas1, A Gonzalez, E Bancalari, N Claure, C Poole, G Silva-Neto.   

Abstract

OBJECTIVE: To assess the role of specific risk factors that may predispose preterm infants with mild or no initial respiratory distress syndrome to the development of chronic lung disease (CLD). STUDY
DESIGN: Clinical data were collected prospectively from 119 ventilator-supported preterm infants with birth weights between 500 and 1000 gm, who survived more than 28 days and required fewer than 3 days of treatment with fraction of inspired oxygen > 25% during the first 5 days of life. Logistic regression analysis was used in a multivariate assessment of risk factors for CLD.
RESULTS: Chronic lung disease occurred in 44 of the patients (37%). The analysis showed that low birth weight, patent ductus arteriosus (PDA), and sepsis were significant risk factors for CLD. The corresponding odds ratios for CLD and their 95% confidence intervals (CI) were as follows: 2.9 per 100 gm birth weight decrement (CI, 1.7 to 4.8); 6.2 (CI, 2.1 to 18.4) for PDA; and 4.4 (CI, 1.3 to 14.5) for sepsis. When sepsis and PDA occurred simultaneously, the odds ratio for CLD increased to 48.3 (CI, 6.3 to > 100) in comparison with infants without these conditions. Episodes of PDA were categorized as either early (occurring during the first week of life) or late (after the first week), and the respective odds ratios for CLD were 2.8 (CI, 0.8 to 9.4) and 21.1 (CI, 5.6 to 80) in comparison with infants without PDA. For the duration of symptomatic PDA, the odds ratio for CLD was 3.5 per week that the PDA remained open (CI, 1.9 to 6.5).
CONCLUSION: CLD is a frequent sequela in very low birth weight infants with mild or no respiratory distress syndrome. In this population, the development of late episodes of PDA, usually in association with a nosocomial infection, seems to play a primary role in the pathogenesis of CLD.

Entities:  

Mesh:

Year:  1995        PMID: 7699543     DOI: 10.1016/s0022-3476(95)70362-4

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  80 in total

Review 1.  Long term sequelae of bronchopulmonary dysplasia (chronic lung disease of infancy).

Authors:  E Eber; M S Zach
Journal:  Thorax       Date:  2001-04       Impact factor: 9.139

2.  Randomised trial of fluid restriction in ventilated very low birthweight infants.

Authors:  V Kavvadia; A Greenough; G Dimitriou; R Hooper
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-09       Impact factor: 5.747

3.  Infection with Ureaplasma urealyticum: is there a specific clinical and radiological course in the preterm infant?

Authors:  U Theilen; A J Lyon; T Fitzgerald; G M A Hendry; J W Keeling
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-03       Impact factor: 5.747

Review 4.  Pathogenesis and treatment of bronchopulmonary dysplasia.

Authors:  Jason Gien; John P Kinsella
Journal:  Curr Opin Pediatr       Date:  2011-06       Impact factor: 2.856

Review 5.  Patent ductus arteriosus: lack of evidence for common treatments.

Authors:  Carl L Bose; Matthew M Laughon
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-11       Impact factor: 5.747

6.  Towards rational management of the patent ductus arteriosus: the need for disease staging.

Authors:  Patrick J McNamara; Arvind Sehgal
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-11       Impact factor: 5.747

Review 7.  Inflammatory mediators in the immunobiology of bronchopulmonary dysplasia.

Authors:  Rita M Ryan; Qadeer Ahmed; Satyan Lakshminrusimha
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

Review 8.  Prevention and treatment of bronchopulmonary dysplasia: contemporary status and future outlook.

Authors:  Laura Cerny; John S Torday; Virender K Rehan
Journal:  Lung       Date:  2008-01-30       Impact factor: 2.584

9.  Patent ductus arteriosus therapy: impact on neonatal and 18-month outcome.

Authors:  Juliette C Madan; Douglas Kendrick; James I Hagadorn; Ivan D Frantz
Journal:  Pediatrics       Date:  2009-02       Impact factor: 7.124

Review 10.  Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants.

Authors:  Geraldine Ng; Orlando da Silva; Arne Ohlsson
Journal:  Cochrane Database Syst Rev       Date:  2016-12-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.